These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 163138)

  • 1. Thymus-dependent lymphocyte levels in bronchogenic carcinoma: correlations with histology, clinical stage, and clinical course after surgical treatment.
    Dellon AL; Potvin C; Chretien PB
    Cancer; 1975 Mar; 35(3):687-94. PubMed ID: 163138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymus-dependent lymphocyte levels during radiation therapy for bronchogenic and esophageal carcinoma: correlations with clinical course in responders and nonresponders.
    Dellon AL; Ptovin C; Chretien PB
    Am J Roentgenol Radium Ther Nucl Med; 1975 Mar; 123(3):500-11. PubMed ID: 164781
    [No Abstract]   [Full Text] [Related]  

  • 3. Skin test in bronchogenic carcinoma. I. Correlation of the immunological status and the extent of the disease.
    Takita H; Brugarolas A
    J Surg Oncol; 1973; 5(4):315-8. PubMed ID: 4355620
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immune status of patients with bronchial cancer].
    Aulenbacher P; Manke HG; Drings P
    Klin Wochenschr; 1987 May; 65(10):445-52. PubMed ID: 3037180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic impairment in bronchogenic carcinoma: a study of lymphocyte response to phytohemagglutinin.
    Han T; Takita H
    Cancer; 1972 Sep; 30(3):616-20. PubMed ID: 4342406
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolonged survival in bronchogenic carcinoma associated with HL-A antigens W-19 and HL-A5: a preliminary report.
    Dellon AL; Rogentine GN; chretien PB
    J Natl Cancer Inst; 1975 Jun; 54(6):1283-6. PubMed ID: 1133845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunomorphology of lymph nodes and prognosis in lung cancer].
    Di Giorgio A; Sammartino P; Canavese A; Arnone P; Sibio S; Accarpio F; Al Mansour M
    Minerva Chir; 2001 Apr; 56(2):153-9. PubMed ID: 11353348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pre-treatment lymphocyte count and T cell levels in localized bronchogenic carcinoma.
    Dellon AL; Potvin C; Chretien PB
    J Surg Oncol; 1979; 12(3):253-61. PubMed ID: 228122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [T-Lymphocyte shifts in patients with melanoma and bronchogenic carcinoma (author's transl)].
    Pichler WJ; Stingl G; Micksche M; Neumann H; Knapp W
    Wien Klin Wochenschr; 1976 Nov; 88(21):707-9. PubMed ID: 1087506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocompetence of patients with bronchogenic carcinoma.
    Olkowski ZL; McLaren JR; Mansour KA
    Ann Thorac Surg; 1976 Jun; 21(6):546-51. PubMed ID: 179484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic status in lung cancer.
    Brugarolas A; Takita H
    Chest; 1973 Oct; 64(4):427-30. PubMed ID: 4355273
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin test.
    Israel L; Mugica J; Chahinian P
    Biomedicine; 1973 Feb; 19(2):68-72. PubMed ID: 4354467
    [No Abstract]   [Full Text] [Related]  

  • 13. Microcytotoxicity assays of tumor immunity in patients with bronchogenic carcinoma correlated with clinical status.
    Pierce GE; DeVald B
    Cancer Res; 1975 Dec; 35(12):3577-84. PubMed ID: 1192421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Demonstration of antibodies against tumor-associated antigens in the serum patients with bronchogenic carcinoma using anticomplement immunofluorescence on xenotransplants of human tumors].
    Stiller-Winkler R; Stark M; Idel H
    Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Mar; 180(4):381-93. PubMed ID: 2988233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival in bronchogenic carcinoma.
    Ashor GL; Kern WH; Meyer BW; Lindesmith GG; Stiles QR; Tucker BL; Jones JC
    J Thorac Cardiovasc Surg; 1975 Oct; 70(4):581-9. PubMed ID: 170481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunological monitoring of patients operated on for epidermoid bronchogenic carcinoma].
    Dominioni L; Dionigi R; Cremaschi P; Nascimbene C; Cividini F; Mori A; Pecis C; Asti S; Moncalvo F; Campani M
    Chir Ital; 1981 Feb; 33(1):47-59. PubMed ID: 7261218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered expression of human monocyte Fc receptors in malignant disease.
    Rhodes J
    Nature; 1977 Jan; 265(5591):253-5. PubMed ID: 189209
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of modified Stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach.
    Newman SB; DeMeester TR; Golomb HM; Hoffman PC; Little AG; Raghavan V
    J Thorac Cardiovasc Surg; 1983 Aug; 86(2):180-5. PubMed ID: 6308356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor associated antigen with pulmonary neoplasms.
    Lo Gerfo P; Herter FP; Braun J; Hansen HJ
    Ann Surg; 1972 Apr; 175(4):495-500. PubMed ID: 4336486
    [No Abstract]   [Full Text] [Related]  

  • 20. [Multiple primary bronchogenic carcinoma].
    Xu QM
    Zhonghua Zhong Liu Za Zhi; 1991 May; 13(3):204-6. PubMed ID: 1664796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.